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A B S T R A C T
In order to determine the comparative eﬃcacy of vaccines administered intranasally or orally to protect
puppies from disease subsequent to experimental infection with Bordetella bronchiseptica (Bb), a random-
ized controlled trial was performed using 48 approximately 8-week-old speciﬁc pathogen free, Bb naive
Beagle puppies. Puppies were randomized into three groups and administered vaccines containing Bb in-
tranasally or orally, or a placebo intranasally. Twenty-one days later, all dogs were challenge exposed via
aerosol administration of Bb. Clinical signs, nasal bacterial shedding and immune responses were moni-
tored for 28 days after challenge. Intranasally vaccinated puppies had signiﬁcantly lower rates of coughing,
nasal discharge, retching and sneezing (i.e. were less sick clinically) than control puppies. The distinction
between the orally vaccinated puppies and the control puppies was less consistent. The orally vaccinated
puppies had less coughing and less retching than the control puppies, but nasal discharge and sneezing
did not differ from control animals. Orally vaccinated puppies had higher rates of coughing, nasal dis-
charge, retching and sneezing than the intranasally vaccinated puppies. Although both intranasal and oral
Bb vaccines stimulated immune responses associated with disease sparing following Bb infection, the in-
tranasal route of delivery conferred superior clinical outcomes. The observed difference in clinical eﬃcacy
suggests the need to question the rationale for the use of currently available orally administered Bb vaccines.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Bordetella bronchiseptica (Bb) is a Gram negative bacterium recog-
nized as one of a constellation of agents etiologically associated with
the canine respiratory disease complex (CIRD) (M’Gowan, 1911; Ford,
2006). Once its role as a canine respiratory pathogen was deﬁnitively
established in the early 1970s (Wright et al., 1973), single component
and combination vaccines for the agent, ﬁrst parenteral, then intrana-
sal, were developed (Ellis, 2015). Recently a single component oral Bb
vaccinewas licensed for commercial use (Hess et al., 2011; Ellis, 2015).
Given the relative ease of administration, the oral Bb vaccine has
replaced vaccines for this pathogen administered by other routes
in many veterinary practices. Since Bb vaccines ﬁrst became avail-
able and commonly used in dogs, there have been differing opinions
regarding the eﬃcacy and mechanisms of protection of the various
routes of administration (Ellis, 2015). Recently, there has been con-
troversy regarding the relative eﬃcacy of the oral and intranasal
routes for mucosal administration; vaccines administered by these
routes have been used as both primary immunogens and as ‘last
minute’ prophylactics prior to commingling. The aim of this study
was to compare the eﬃcacy of representative intranasal and oral
vaccines for Bb, and to examine immune responses, including those
at the mucosa at the earliest documented onset of clinical immu-
nity (72 h; Gore et al., 2005).
Materials and methods
Experimental subjects
Forty-eight (24 male, 24 female) weaned, speciﬁc pathogen free Beagle dogs,
aged 56–62 days, were obtained from a commercial breeder (Ridglan Farms) and
acclimated for 7 days at the study site. The puppies had received a single compo-
nent vaccine against canine parvovirus (NeoPar, NeoTech) at 6 weeks of age. All dogs
had low or no antibodies against Bb (<1:16 by microagglutination test, MAT; Ellis
et al., 2001) and were determined to be free of Bb by deep nasal swab cultures on
day 0 prior to vaccination. All dogs were maintained and handled using proce-
dures consistent with the United States Department of Agriculture 9CFR, and approved
by the Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC), and had access to ad libitum dry food and water.
Vaccines
A single component oral Bb vaccine (Bronchi-shield ORAL, Boehringer Ingelheim
Vetmedica) was obtained commercially from a distributor. A triple component
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(‘3-way’) intranasal vaccine (Vanguard Rapid Resp, Zoetis) containing Bb, canine para-
inﬂuenza virus (CPIV) and canine adenovirus-2 (CAV-2) was obtained from the
manufacturer. Both vaccines contain ‘live avirulent cultures’ of Bb; however, the spe-
ciﬁc isolates of the bacteria and the dose in the vaccines are considered proprietary.
Experimental design and housing
Dogs were randomized using a software program (SPSS, SAS Institute). Puppies
were blocked in groups of six by date of birth and dam, and assigned to treat-
ments within blocks (two per treatment). Treatments were randomly assigned to
rooms for the vaccination phase of the study. Within vaccination rooms, blocks were
randomly assigned to pens. During the vaccination phase, the 48 puppies were divided
into three treatment groups: (1) the control group received 0.5 mL of sterile diluent
(distilled water) intranasally; (2) the second group received 1.0mL of the single com-
ponent vaccine orally between the cheek and lateral gum; and (3) the third group
received 0.5 mL of the three-way vaccine in one nare. The dogs were housed two
per pen in three separate biosecure isolation rooms. To further reduce the chances
for exposure to Bb, the room housing the control puppies was entered ﬁrst; there-
fore, observers were not masked to treatment groups during the vaccination phase.
On day 20 (the day before the challenge on day 21), the dogs were co-mingled in
three rooms; three blocks were randomly assigned to two challenge rooms and two
blocks to one challenge room. Within each room, there were six puppies per double
pen (two dogs from each treatment group) (see Appendix: Supplementary Fig. S1).
All personnel performing clinical evaluations (during the challenge phase), labora-
tory testing and analyses were ‘masked’ (unaware of treatment groups). This protocol
was approved by IACUC committee at the study site (approval number KZ-1894e2013-
10-ajb; year of approval 2013).
Bordetella bronchiseptica inoculum and experimental infection
The virulent Bihr (feline origin) Bb strain was used as the inoculum and was cul-
tured on selective (Bordet Gengou, BG) agar from stock as previously described (Ellis
et al., 2001). The number of bacteria was adjusted nephelometrically (optical density,
OD, 600) to approximately 4 × 1010 colony forming units (CFUs)/mL. Dogs were chal-
lenged six at a time via aerosolization of 25mL of inoculum containing approximately
6 × 108 CFUs Bb (target of 1 × 108 CFUs per dog) into a chamber. Dogs remained in
the chamber for a total of 30–35 min.
Clinical assessment and sampling
General health observations were completed on all puppies from the day of arrival
(day −7) to study completion (day 49). Puppies were observed prior to and approx-
imately 3 h post-vaccination for any adverse reactions. Puppies were observed twice
on day 20 (prior to and approximately 3–4 h after co-mingling), twice on day 21
(prior to and approximately 4–5 h post-challenge), then twice daily (morning and
afternoon for 30min per group) on days 22–48, and once on day 49. During the chal-
lenge phase, puppies were clinically scored according to a predetermined rubric
(Table 1) focusing on the primary outcome variable, spontaneous coughing. Rectal
temperatures were recorded during the morning observation period on days −1 and
0, and on days 20–49.
Nasal swabs for bacterial culture were collected on day 0, twice weekly (Tuesday,
Thursday) until day 20, on day 21 and then thriceweekly (Monday,Wednesday, Friday)
on days 21–49, and placed in tryptose phosphate broth transport medium. Nasal
and oropharyngeal swabs were collected on days 0 and 3, and placed in 1 mL
Dulbecco’s modiﬁed Eagles transport medium for measurement of mucosal immu-
noglobulin (Ig) A (IgA) and interferon α (IFNα). Serum was obtained on days 0, 3,
20 and 49.
Bacteriological culture
Nasal swabs were streaked onto BG agar plates as previously described (Ellis et al.,
2001). The identity of suspect colonies was conﬁrmed by matrix-assisted laser
desorption/ionization (MALDI; Patel, 2015) using a commercial apparatus (Microﬂex
LT, Bruker Daltonics).
Quantitation of Bordetella bronchiseptica-reactive antibodies
MATs and ELISAs to measure Bb reactive IgG and IgA were performed as previ-
ously described (Harris and Switzer, 1972; Ellis et al., 2001).
Quantitation of canine interferon α
A capture ELISA for canine IFNα (Cloud Clone) was performed according to the
manufacturer’s instructions. The protein contents of nasal swab samples were de-
termined using a colorimetric assay (Bradford, 1976) for comparison with OD values
obtained in the capture (and IgA) ELISAs.
Statistical analyses
Descriptive statistics were conducted for the pre-challenge (vaccination) phase
of the trial and descriptive and inferential statistics were conducted on the post-
challenge data. In all inferential analyses, each treatment was compared to every
other treatment (control versus oral vaccinates, control versus intranasal vacci-
nates, oral vaccinates versus intranasal vaccinates).
Post-challenge, the puppies were observed and scored for seven clinical signs
using a Likert scale (score range 0–3; Table 1). Scoring was performed twice daily
Table 1
Clinical scoring rubric.
Clinical sign Score Description
Nasal discharge 0 Absent: Includes normal, moist nose
1 Mild: Serous (clear, watery) discharge, must be extending approximately half way down the nasal philtrum
2 Moderate: Serous discharge extending more than half way down the nasal philtrum, or evidence of mucopurulent discharge
3 Severe: Mucopurulent discharge extending more than half way down the nasal philtrum, or bloody discharge, or a combination of
mucopurulent and bloody discharge
Ocular discharge 0 Absent
1 Mild: Evidence of excessive tear production (brimming and/or ﬂowing out of the eye), such as some secretion in the corner of the eye or
brimming with tears
2 Moderate: Serous discharge extending more than half way down the nasal philtrum, or evidence of mucopurulent discharge
3 Severe: Mucopurulent discharge extending more than half way down the nasal philtrum, or bloody, or bloody discharge, or a
combination of mucopurulent and bloody discharge
Cough 0 Absent
1 Mild: One cough episode
2 Moderate: Spontaneous and frequent coughing; two or more coughing episodes
3 Severe: Spontaneous coughing with frequent retching; animal had persistent and prolonged cough
Sneezing 0 Absent
1 Mild: Animal sneezed once or twice
2 Moderate: Animal sneezed repeatedly
3 Severe: Animal presented paroxysmal sneeze
Depression 0 Absent
1 Mild: Animal is slow to rise, lost interest in playing but still somewhat active
2 Moderate: Animal is able to rise and move, but inactive other than to eat or drink
3 Severe: Animal is recumbent, unable to rise, and refuses food and/or drink
Retching 0 Absent
1 Mild: Animal retches or vomits once brieﬂy or occasionally
2 Moderate: Animal retches or vomits for a prolonged period
3 Severe: Animal retches or vomits multiple times for a prolonged period
Respiration 0 Normal respiration
2 Moderate: Small clicking, bubbling, or rattling sounds in the lung (rales)
3 Severe: Diﬃcult or labored breathing; shortness of breath (dyspnea)
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for 27 days and once on day 28 for a total of 55 observation periods. For the post-
vaccination time frame, for each clinical outcome in Table 1, data were summarized
by counting the number of times each puppy was observed to have scored ≥1 (at
least mild signs), ≥2 (moderate or severe signs) or 3 (severe signs) (Table 2) (Dohoo
et al., 2009). After summarizing each clinical sign in this manner, for each of the
above three categories, a separate generalized linear mixed model (GLMM), with a
negative binomial distribution and the offset set as the log of the number of obser-
vations, was performed (Table 3). Potential clustering within room and pen was
accounted for using random intercepts and the only independent variable in each
model was treatment group. A GLMM model with a Poisson distribution was per-
formed for the outcome count of days that a puppy shed Bb post vaccination, with
an offset of the log of the total number of observations, and room and pen effects
accounted for as random intercepts.
All GLMMmodel results were reported as incidence rate ratios (IRRs) with 95%
conﬁdence intervals (95% CIs) (Dohoo et al., 2009). An incidence rate ratio mea-
sures the number or counts of new events in a deﬁned population in a speciﬁed
period of time. For example, in comparing mild coughing between control and oral
vaccinated puppies, an IRR of 1.5 would indicate that the frequency of coughing was
50% higher in the control group than in the oral vaccinates; alternatively, the in-
terpretation would be that the rate of coughing in control puppies was 1.5 times
higher than in orally vaccinated puppies.
To obtain an approximately normal distribution, serum IgG and IgAwere log trans-
formed and a linear multilevel mixed effects model with the log transformation for
either IgG or IgA, separately, was constructed with treatment group as the inde-
pendent variable, and room and pen as random effects. Transformation of the MAT
serum dilutions to approximate a normal distribution was unsuccessful; therefore,
a nonparametric Kruskal–Wallis test was performed. All analyses were performed
using commercial statistical software (STATA V13.1, StataCorp). As a result of the mul-
tiple outcomes of interest, a Bonferroni adjustment wasmade to provide conservative
estimates of statistical signiﬁcance (P ≤ 0.002) and offset the chance of a type I error
(Dohoo et al., 2009).
Results
No adverse effects were noted following vaccine administra-
tion. For each clinical sign, results are presented as a count of the
number of times that puppies within treatment groups were scored
as ≥1 (at least mild clinical signs), ≥2 (moderate to severe clinical
signs) or 3 (severe clinical signs) over the 55 observations con-
ducted in the post-vaccination period. The median and range
(minimum and maximum) of counts are summarized in Table 2.
These data demonstrate that coughing scores were particularly vari-
able between each group. Intranasally vaccinated puppies had lower
counts of coughing, nasal discharge, retching and sneezing than the
control group or the orally vaccinated puppies.
Statistically signiﬁcant differences between the treatment groups
and the clinical signs are summarized in Table 3. As an example of
the interpretation of the data in Table 3 for a comparison of control
puppies with oral vaccinated puppies, the rate of mild coughing in
control puppies was 2.2 (95% CI 1.5–3.5) times higher than in orally
vaccinated puppies (P < 0.0001). Intranasally vaccinated puppies had
signiﬁcantly lower rates of nasal discharge, coughing, sneezing and
retching than control puppies. Orally vaccinated puppies had less
coughing and retching than control puppies, but nasal discharge and
sneezing did not differ from controls. Orally vaccinated puppies had
higher rates of coughing, nasal discharge, retching and sneezing than
intranasally vaccinated puppies (Fig. 1).
Nodifferencesweredetected in the rates of ocular dischargebetween
the groups for any score of ocular discharge (at leastmild, at leastmod-
erate or severe) (P > 0.30). All puppies in the intranasally vaccinated
group had no abnormal lung sounds over the duration of the study. In
puppies with abnormal lung sounds, there were no signiﬁcant differ-
ences in the frequency of having moderate to severe lung sounds
between the control group and the orally vaccinated puppies (P =0.02).
No puppies in any groupwere scored as having severe labored breath-
ing anddyspnea.Onedog in the three-way intranasally vaccinatedgroup
had a single dayof pyrexia (>39.5 °C; day47); no signs of systemic illness
were observed in any of the dogs after challenge.
Bacteriological ﬁndings
The median duration of shedding Bb was 12 (range 10–12) days
for control dogs, 12 (range 1–13) days for orally vaccinated dogs
and 9 (range 2–12) days for intranasally vaccinated dogs. There was
no signiﬁcant difference in the rate of shedding between the orally
vaccinated dogs and the control group (P = 0.37). The rate of shed-
ding of Bb in control puppies was 1.5 (95% CI 1.2–1.8) times higher
than in intranasally vaccinated puppies (P = 0.001), whereas there
was no signiﬁcant difference in the rate of shedding between orally
vaccinated and intranasally vaccinated puppies (P = 0.02).
Table 2
Summary of the number of observations (outcomes) post-challenge that puppies were scored as at least a 1, at least a 2, or at least a 3, using the scale in Table 1, and for
clinical signs and treatment groups listed.
Puppy scored with at least a minimum valuea Outcome Treatment group
Control Orally
vaccinated
Intranasally
vaccinated
Median Range Median Range Median Range
1 (at least mild clinical signs) Cough 22 11–36 6 0–26 2 0–9
Ocular discharge 13 0–51 12 3–45 16 0–49
Sneezing 2 0–5 2 0–6 0 0–2
Depression 0 0 0 0 0 0
Retching 8 0–18 1 0–12 1 0–5
Abnormal lung sounds 2 0–4 0 0–6 0 0
Nasal discharge 1 0–5 0 0–2 0 0–1
2 (at least moderate or severe clinical signs) Cough 20 0–31 4 0–19 1 0–6
Ocular discharge 0 0–15 1 0–15 1 0–15
Sneezing 0 0–1 0 0–2 0 0
Depression 0 0 0 0 0 0
Retching 1 0–5 0 0–4 0 0
Abnormal lung sounds 2 0–4 0 0–6 0 0
Nasal discharge 0 0–1 0 0 0 0
3 (severe clinical signs) Cough 1 0–3 0 0–3 0 0
Ocular discharge 0 0–1 0 0–1 0 0–2
Sneezing 0 0 0 0 0 0
Depression 0 0 0 0 0 0
Retching 0 0 0 0 0 0
Abnormal lung sounds 0 0 0 0 0 0
a Using the clinical sign scoring rubric over the 55 day post-vaccination observation period.
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Onset of local immunity
Mucosal Bb reactive IgA and IFN-α concentrations were low (<5 U
in IgA ELISA; few picograms in IFN assay) and undetectable in most
nasal swab samples at day 0 prior to vaccination. There was no in-
crease in either of these solublemediators at 3 days after vaccination;
values were consistently low or undetectable. Hence, any re-
sponses were considered biologically irrelevant and there were no
apparent differences among treatment groups (data not shown); no
further analyses were performed.
Antibody responses
No signiﬁcant differences between any of the groups were de-
tected in theMAT results at day 0 (P = 0.51; Fig. 2). The control group
had signiﬁcantly lower MAT serum dilutions at days 20 (P < 0.0001)
and 49 (P = 0.002) than the intranasally vaccinated group. The control
group also had signiﬁcantly lower MAT serum dilutions at day 20
(P < 0.0001), but not at day 49 (P = 0.06), than the orally vacci-
nated dogs. No differences were detected between orally and
intranasally vaccinated groups for either day 20 (P = 0.03) or day
49 (P = 0.32). All dogs had moderate to high concentrations of Bb
reactive IgA in serum from day 49 (control: median 96 U, range 39–
440 U; orally vaccinated: median 89 U, range 40–200 U; intranasally
vaccinated: median 97 U, range 38–181 U). There were no signiﬁcant
Table 3
Summary of the statistical comparisons of the three treatment groups for each outcome of interest by categorization of clinical scores as ≥1, ≥2 or 3.
Outcome Treatment group comparisons Incident rate ratio 95% Conﬁdence interval P value
Score ≥1
Coughing Control versus oral vaccination 2.2 1.5–3.5 <0.0001
Control versus intranasal vaccination 6.9 4.2–11.3 <0.0001
Oral vaccination versus intranasal vaccination 3 1.8–5.3 <0.0001
Nasal discharge Control versus oral vaccination No difference – 0.87
Control versus intranasal vaccination 1.8 1.3–2.3 <0.0001
Oral vaccination versus intranasal vaccination 1.7 1.3–2.3 <0.0001
Sneezing Control versus oral vaccination No difference – 0.9
Control versus intranasal vaccination 5.8 2.2–14.9 <0.0001
Oral vaccination versus intranasal vaccination 5.6 2.2–14.5 <0.0001
Retching Control versus oral vaccination 3.2 1.7–6.3 <0.0001
Control versus intranasal vaccination 10.6 4.7–23.8 <0.0001
Oral vaccination versus intranasal vaccination No difference 2.2–14.5 0.005
Score ≥2
Coughing Control versus oral vaccination 2.8 1.7–4.5 <0.0001
Control versus intranasal vaccination 11.6 6.5–21.0 <0.0001
Oral vaccination versus intranasal vaccination 4.2 2.3–7.7 <0.0001
Nasal discharge Control versus oral vaccination No difference – >0.02
Control versus intranasal vaccination No difference – >0.02
Oral vaccination versus intranasal vaccination No difference – >0.02
Coughing Control versus oral vaccination 2.8 1.7–4.5 <0.0001
Control versus intranasal vaccination 11.6 6.5–21.0 <0.0001
Oral vaccination versus intranasal vaccination 4.2 2.3–7.7 <0.0001
Sneezing Control versus oral vaccination No difference – 0.9
Control versus intranasal vaccination No dogs scored as moderate – NA
Oral vaccination versus intranasal vaccination No difference – NA
Retching Control versus oral vaccination No difference – 0.15
Control versus intranasal vaccination No difference – 0.99
Oral vaccination versus intranasal vaccination Model won’t converge – NA
Score 3
Coughing Control versus oral vaccination No difference – >0.02
Control versus intranasal vaccination No difference – >0.02
Oral vaccination versus intranasal vaccination No difference – >0.02
Nasal discharge Control versus oral vaccination No dogs scored as severe – NA
Control versus intranasal vaccination No dogs scored as severe – NA
Oral vaccination versus intranasal vaccination No dogs scored as severe – NA
Sneezing Control versus oral vaccination Model won’t converge – NA
Control versus intranasal vaccination No dogs scored as severe – NA
Oral vaccination versus intranasal vaccination No dogs scored as severe – NA
Retching Control versus oral vaccination No dogs scored as severe – NA
Control versus intranasal vaccination No dogs scored as severe – NA
Oral vaccination versus intranasal vaccination No dogs scored as severe – NA
NA, not applicable.
Fig. 1. Scatter (bee swarm) plot of coughing in puppies after infection with Bordetella
bronchiseptica. Each symbol represents the count of observations post-challenge in
which an individual puppy was scored as having at least a mild cough (i.e. ≥1; Table 1)
in each treatment group (controls: black triangles, n = 16; orally vaccinated: dark
gray triangles, n = 16; intranasally vaccinated: light gray triangles, n = 16). The black
horizontal lines represent the median number of observations that puppies scored
≥1 for coughing for each treatment group.
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differences among groups in Bb reactive IgG on day 49 (control:
median 65 U, range 46–91 U; orally vaccinated: median 60 U, range
29–80 U; intranasally vaccinated: median 57 U, range 42–80 U;
P > 0.07).
Discussion
The results of this study conﬁrm previous observations (Ellis,
2015) that mucosal delivery of modiﬁed live Bb by either the in-
tranasal or oral route can effectively immunize dogs and confer
sparing of CIRD, as assessed in a robust challenge model. In the
present study, the intranasal route engendered superior protec-
tive immunity against clinical signs typical of Bb associated ‘kennel
cough’. These results contrast with the equivalent clinical out-
comes following intranasal or oral immunization reported in the
one other published comparative study (Larson et al., 2013). However,
the previous study had issues with experimental design and no sta-
tistical analyses were undertaken, rendering the conclusions drawn
therein questionable (Ellis, 2015).
Arguably, a more relevant comparison than the one reported
herein would have been to evaluate the response to a three-way
vaccine administered either intranasally or orally; however, cur-
rently there are no licensed three-way oral vaccines. Despite this,
a three-way combination vaccine is likely to represent a rational
approach to immunoprophylaxis, given the commonality of mul-
tiple infections currently documented in dogs with respiratory
disease (Schulz et al., 2014; Joffe et al., 2016).
Strictly speaking, the results reported herein are only applica-
ble to the vaccines tested. It is possible that different oral and
intranasal Bb vaccines (i.e. different formulations or different doses
of Bb) may engender different immune responses and affect differ-
ent clinical outcomes after challenge. However, notwithstanding that
caveat, we think these results truly reﬂect generic differences
between the relative eﬃcacy of oral versus intranasal delivery in
stimulating disease-sparing responses to Bb and probably other re-
spiratory pathogens.
In large part, the superior eﬃcacy of intranasal versus oral ad-
ministration may simply be a consequence of more extensive
distribution of antigen, exposing both nasal associated lymphoid
tissue (Kiyono and Fukuyama, 2004), as well as the retropharyngeal
tonsil (adenoid), which is unique among tonsils with its overlying
layer of respiratory epithelium (Billen et al., 2006). Both sites are
important sites of immune induction and neither would be exposed
to antigen by oral administration of vaccine (Kiyono and Fukuyama,
2004). Beyond their use as primary immunogens, mucosally deliv-
ered vaccines are frequently used immediately prior to boarding
(housing dogs in communal kennels) or other potentially high chal-
lenge situations, the rationale being that mucosal delivery induces
a local and more rapid response.
It is often assumed, from a mechanistic standpoint, that IgA is
responsible for any disease reduction (Gore et al., 2005; Davis et al.,
2007). Our examination of innate and adaptive immune responses
at 0 and 72 h after vaccination readdressed this issue. The 72 h time
point was speciﬁcally chosen because it was the earliest onset of
immunity reported in the one published study (Gore et al., 2005);
however, local immune responses were not reported in that study.
Perhaps predictably, based on the current understanding of anti-
body production involving class switching andmaturation of plasma
cells from stimulated B cells (Strungell andWijburg, 2010) we found
little, or mostly no, detectable IgA 72 h after either intranasal or oral
immunization in either nasal or oral secretions.
In one of few studies reporting local immune responses, Bb re-
active IgA in nasal secretions was not detected until more than 21
days after primary intranasal vaccination (Davis et al., 2007). On the
basis of studies in cattle (Todd et al., 1973) and Bb infected cats
(Bradley et al., 2012), it is probable that innate immune responses
are responsible for disease reduction in the ﬁrst few days after
mucosal vaccination. We attempted to measure type I interferon
(IFN-α). Unfortunately little or mostly no INF-αwas detected in nasal
or oral secretions of mucosally vaccinated puppies at 72 h. This could
be the result of inadequate sample volume, the failure of the com-
mercial capture ELISA to detect INF-α in the types of samples tested
or the possibility that other soluble mediators of the innate immune
system are the effectors stimulated by mucosal vaccination (Kumar
et al., 2011).
Nevertheless, these negative results and still unresolved mech-
anistic uncertainties should not preclude the use of mucosally
delivered vaccines in this common application. Again, from an im-
munologically rational standpoint, the use of intranasal combination
vaccines makes more sense than a single component oral vaccine
based on the number of different biochemical motifs or pathogen
associated molecular patterns (PAMPs; Kumar et al., 2011) in the
three-way intranasal formulation, including negative stranded viral
RNA, viral DNA, and viral glycoproteins, in addition to the CpG DNA
motifs, endotoxin and ﬂagellin in Bb. Intranasal delivery would result
in more extensive exposure to PAMPs and stimulation of the innate
immune response in both the nasal cavity and oropharynx.
The MAT is one of the classic tests used to assess the eﬃcacy
of vaccines for human whooping cough caused by B. pertussis (Bp),
the closely related descendent of Bb (Miller et al., 1943; van der Ark
et al., 2012). It is often stated or implied that serum antibody re-
sponses are largely irrelevant to clinical immunity in Bb infections
in dogs (Ford, 2006; Davis et al., 2007; Hess et al., 2011; Larson et al.,
2013); however, the correlation between serum antibody, notably
MAT, and disease-sparing was documented more than 70 years ago
in large numbers of vaccinated and naturally Bp infected children
(Miller et al., 1943). The protective role of serum antibodies in Bp
vaccines was further characterized with antigen speciﬁc ELISAs 20
years ago (Cherry et al., 1998).
Previously, we demonstrated a similar relationship between clin-
ical immunity and serum antibodies in Bb infected dogs, following
immunization with either or both intranasal and parenteral vac-
cines (Ellis et al., 2001). In the present study, the intranasally
vaccinated dogs had numerically higher MATs than the control and
Fig. 2. Median microagglutination titer (MAT) serum dilutions for each treatment
group on days 0, 20 and 49 of the study. The dark gray bars represent the control
group, the light gray bars represent the orally vaccinated group and the black bars
represent the intranasally vaccinated group. Signiﬁcant differences: aNo signiﬁcant
differences detected between any of the groups (P ≥ 0.05); bSigniﬁcant differences
detected between the control and orally vaccinated groups and between the control
and the intranasally vaccinated groups (P < 0.05); cNo signiﬁcant differences de-
tected between the orally and intranasally vaccinated groups (P ≥ 0.05); dSigniﬁcant
differences detected between the control and the intranasally vaccinated groups
(P < 0.05); eNo signiﬁcant differences detected between the control and the orally
vaccinated groups and between the orally and intranasally vaccinated groups (P < 0.05).
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orally vaccinated animals; however, the stringency of the analyses
for signiﬁcance (P < 0.002) required when conducting multiple com-
parisons (Dohoo et al., 2009) most likely precluded the detection
of signiﬁcant differences between vaccine groups. Furthermore, the
time of sampling may have been a factor in not detecting differ-
ences, which may have been revealed in anamnestic responses
within days to a week after challenge (Ellis et al., 2001). Overall, the
immunological results of this study replicated previous ﬁndings (Ellis
et al., 2001), albeit, as in the previous study, mucosal immuniza-
tion resulted in less pronounced systemic (MAT) responses (than
parenteral immunization), as would be expected.
At least in part based on our previous experience with high vari-
ation in sampling of mucosal secretions in dogs (Ellis et al., 2002),
and diﬃculties in obtaining consistent nasal samples, especially in
young puppies with small nares, we used serum IgA as a surro-
gate for mucosal IgA to further characterize the anamnestic response
following challenge. This approach is validated by classical studies
with canine IgA in normal dogs and dogs with selective IgA deﬁ-
ciency, as well as studies in human beings infected with inﬂuenza
virus (Vaerman and Heremans, 1970; Brown et al., 1985; Batt et al.,
1991; Olsson et al., 2014). IgA in dog serum is predominately dimeric
(Vaerman and Heremans, 1970) and is thought to be primarily pro-
duced at mucosal surfaces (Vaerman and Heremans, 1970; Batt et al.,
1991; Olsson et al., 2014).
Our ﬁnding of no differences among treatment groups in the con-
centrations of Bb reactive IgA (or IgG) in serum 28 days after
challenge could also be a function of the timing of sampling. Earlier
sampling after challenge may have revealed differences in anam-
nestic responses, as we previously demonstrated in samples collected
on day 3 after experimental exposure to Bb (Ellis et al., 2001). Nev-
ertheless, the ﬁnding of moderate to high concentrations of Bb
reactive IgA in serum of all dogs following only mucosal exposure
to the non-invasive bacteria supports the seminal observations that
IgA is primarily produced by plasma cells in the lamina propria of
mucosae. It then ‘spills over’ into the systemic circulation (Vaerman
and Heremans, 1970), where it can be more easily and consis-
tently measured by sampling of plasma.
Conclusions
The results of this study indicate that, although mucosal deliv-
ery of the intranasal and oral Bb vaccines resulted in signiﬁcant
disease sparing as a result of primary immunization, the intrana-
sal vaccine conferred superior clinical immunity. Furthermore, these
results should question the medical rationale for routine use of oral
Bb vaccine, notwithstanding its apparent easier administration.
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